Provention Bio Drug Is a Diabetes Win. Now, Where Are the Patients? – Bloomberg

Bloomberg Markets European Open kick starts the trading day, breaking down what’s moving markets and why. Francine Lacqua and Tom Mackenzie live from London bring you an action-packed hour of news no investor in Europe can afford to miss.
Overnight on Wall Street is morning in Europe. Bloomberg Daybreak Europe, anchored live from London, tracks breaking news in Europe and around the world. Markets never sleep, and neither does Bloomberg News. Monitor your investments 24 hours a day, around the clock from around the globe.
European Stocks Advance as Investors Eye China Reopening, Powell
Ring-Fencing Rules Face Chop in Brexit Big-Bang: The London Rush
French Inflation Holds at Record, Defying European Slowdown
Finland Suffers Deeper Contraction as Inflation Hurts Consumers
Thailand Raises Rate a Third Time as Price Pressures Linger
Saudi Official Says No Official FIFA World Cup 2030 Bid
Renault, Airbus to Develop Battery Tech for Cars and Airplanes
Disney Channel, ESPN Each Lost 2 Million Subscribers in Fiscal Year
Saudi Food Delivery Firm Jahez to Buy Chefz in Cash, Stock Deal
Hackers Cripple Prestigious Indian Hospital’s IT Systems
EU Proposes Special Court to Probe Russian Actions in Ukraine
Ukraine Latest: NATO Allies Urged to Send More Battle Tanks
NYC Becomes One Billionaire Family’s Haven From China Property Crash
Norway to Hit Fleeing Billionaires With Higher Exit Tax
Lamborghini Follows Porsche Off-Road With Huracán Sterrato
Hugh Grant Says Love Actually’s Downing Street Dance Scene Is ‘Excruciating’
Recession Probably Scares Retailers More Than China Protests
The Decline and Fall of the Tory Empire
Crypto’s Future Could Look Like Iraq’s Past
TikTok’s Viral Challenges Keep Luring Young Kids to Their Deaths
Global Debt Costs Are Soaring. Here’s Where It Will Hurt Most
Putting Chips in Hoodies and Clogs to Unlock Value for Buyers and Sellers
Tokyo Court Set to Rule on Same-Sex Couples’ Right to Marriage
These 36 Republican Senators Voted No on the Respect for Marriage Act
Dubai Firm Gets $750 Million to Build Wind and Solar Farms in Egypt
Renault, Airbus to Develop Battery Tech for Cars and Airplanes
NYC Faces $300 Million Bill in Lawsuit Over Post-Bail Detention
Fiona Apple Pushes Maryland Courts to Keep Cameras On
How Pandemic Aid Is Boosting a Seattle-Area Tribe
FTX’s LedgerX, a Solvent Corner of SBF’s Fallen Empire, Will Put Millions in Bankruptcy Pot
India to Test Retail Version of Digital Rupee in Thursday Launch
Why Some Investors Refuse to Give Up on Metaverse Land
Teplizumab can delay the onset of Type 1 diabetes by two years, but it’s not easy to identify who needs it. 
Packing for school.
Lisa Jarvis
In a first, the US Food and Drug Administration has approved a therapy that slows the onset of Type 1 diabetes. Teplizumab, developed by Provention Bio, typically delays the need for insulin shots, blood-sugar monitoring, and diet control by about two years. For some, the effect lasted years longer.
The treatment could be a way to delay the life-changing regime of managing diabetes, which is often diagnosed in children or adolescence. Unfortunately, there are many hurdles to overcome before the drug can make a real difference. The most immediate and daunting problem: getting the treatment to the right people at the right time.

source